Lineage Cell Therapeutics (LCTX) Shares Outstanding (Diluted Average) (2014 - 2026)

Lineage Cell Therapeutics has reported Shares Outstanding (Diluted Average) for 13 years, with the latest figure at $261.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 15.54% year-over-year to $261.2 million; the trailing twelve-month figure through Mar 2026 stood at $261.2 million (up 15.54% YoY), and the FY2025 full-year result was $230.1 million, up 14.95% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $261.2 million, up from $230.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $261.2 million in Q1 2026, with the low at $169.6 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $194.0 million across 5 years, with a median of $182.9 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) soared 106781.08% — and 2023, when it gained 0.28%.
• Lineage Cell Therapeutics' Shares Outstanding (Diluted Average) stood at $169.8 million in 2022, then advanced by 1.69% to $172.7 million in 2023, then rose by 15.94% to $200.2 million in 2024, then rose by 14.95% to $230.1 million in 2025, then rose by 13.5% to $261.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $261.2 million (Q1 2026), $230.1 million (Q4 2025), and $227.8 million (Q3 2025), per Business Quant data.